Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Weill Medical College of Cornell University
National Cancer Institute (NCI)
Jiangsu HengRui Medicine Co., Ltd.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Boehringer Ingelheim
Gilead Sciences
AstraZeneca
AstraZeneca
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Mayo Clinic
Lantern Pharma Inc.
Fundación GECP
University of Kentucky
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Latin American Cooperative Oncology Group
BeiGene
University Hospital, Essen
Mirati Therapeutics Inc.
Alliance for Clinical Trials in Oncology
Vanderbilt-Ingram Cancer Center
Bristol-Myers Squibb
Fundación GECP
Fundación GECP
Fox Chase Cancer Center
Fundación GECP
EpicentRx, Inc.
Latin American Cooperative Oncology Group
Hoosier Cancer Research Network
Sun Yat-sen University
Sun Yat-sen University
Shanghai Chest Hospital
BeiGene
Centre Leon Berard
SWOG Cancer Research Network
Rutgers, The State University of New Jersey